| Patient | Sun Yat-sen |
|---|---|
| Date of birth | 1866-11-12 |
| Identifiers | MRN HR-ET016-SYN-TD; SSN (made up) 000-16-4183 |
| Document date | 1924-09-21 |
| Author | Wen-Li Huang, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Periodic adult preventive visit. [S]
Mr. Sun is a 57-year-old physician by training and political leader who comes for his yearly preventive visit, timed with the day-8 infusion of cycle 6, which he had this morning. The cold of three weeks ago cleared within a week without fever. He has been working most days and has kept his weight steady with the dietitian's advice. He meets the palliative care team every three to four weeks and has talked with them about what matters most to him. He asked which preventive services still make sense for him now, and wants the vaccines that protect him during treatment. [S]
| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit, age 57 |
| Cancer treatment | Cycle 6 of gemcitabine, cisplatin and durvalumab; day-8 dose today |
| Recent illness | Cold cleared within a week |
| Weight | Steady at about 59 kg |
| His question | Which preventive services still make sense now |
Health risk assessment. Completed by the patient on the clinic tablet before the visit and reviewed with him by Dr. Huang. [S]
| Domain | Finding |
|---|---|
| Self-rated health | Fair; tired in the afternoons, but working most days |
| Psychosocial | Supported by colleagues and his household; talks openly with the palliative care team |
| Substance use | Alcohol rarely, at formal dinners; none since starting treatment; no drugs |
| Tobacco | Never smoked |
| Physical activity | Walks 30 minutes most days |
| Nutrition | Small frequent meals and a protein drink each day, as the dietitian advised |
| Sleep | Six to seven hours; occasional night waking |
| Infection precautions | Hand hygiene; avoids crowds in the week after day-8 doses; has a thermometer |
| Safety at home | Feels safe; smoke alarm working; no firearm at home |
| Road safety | Wears a seat belt; is driven to most meetings |
| Activities of daily living | Independent |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Afternoon tiredness; no fever; weight steady |
| Eyes | Negative | Reading glasses; no change |
| Ears, nose, mouth, and throat | Negative | Cold resolved; no ringing in the ears or hearing change; no mouth sores |
| Cardiovascular | Negative | No chest pain or leg swelling |
| Respiratory | Negative | Cough gone; no breathlessness |
| Gastrointestinal | Negative | Mild nausea on the two days after each infusion, eased by ondansetron; no jaundice; ache under the right ribs 1 of 10 |
| Genitourinary | Negative | No urinary symptoms |
| Musculoskeletal | Negative | No joint pain |
| Integumentary | Negative | No rash or itching |
| Neurological | Negative | No numbness or tingling |
| Endocrine | Negative | No heat or cold intolerance, thirst, or excess urination |
| Psychiatric | Negative | Mood steady; PHQ-2 score 1 |
12 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 8 hours as needed for right upper abdominal ache; no more than 3,000 mg a day | Two tablets by mouth every 8 hours as needed, no more than 3,000 mg a day | Oral route | 1924-05-04 | active | S |
| Gemcitabine 1,000 mg/m2 (1,660 mg) intravenous infusion on days 1 and 8 of each 21-day cycle | Days 1 and 8 of each 21-day cycle, up to 8 cycles | Intravenous route | 1924-06-01 | active | S |
| Cisplatin 25 mg/m2 (41 mg) intravenous infusion on days 1 and 8 of each 21-day cycle | Days 1 and 8 of each 21-day cycle, up to 8 cycles, with hydration | Intravenous route | 1924-06-01 | active | S |
| Durvalumab 1,500 mg intravenous infusion on day 1 of each 21-day cycle | Day 1 of each 21-day cycle with chemotherapy, then every 4 weeks alone | Intravenous route | 1924-06-01 | active | S |
| Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea | One tablet by mouth every 8 hours as needed for nausea | Oral route | 1924-06-01 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1924-09-21 | Body height | 165 | cm | S |
| 1924-09-21 | Body weight | 59.4 | kg | S |
| 1924-09-21 | Body mass index (BMI) [Ratio] | 21.8 | kg/m2 | S |
| 1924-09-21 | Systolic blood pressure | 122 | mm[Hg] | S |
| 1924-09-21 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1924-09-21 | Heart rate | 80 | /min | S |
| 1924-09-21 | Respiratory rate | 16 | /min | S |
| 1924-09-21 | Body temperature | 36.6 | Cel | S |
| 1924-09-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1924-09-21 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S |
Vital signs recorded on 1924-09-21; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Constitutional | Thin but well; weight 59.4 kg, BMI 21.8; blood pressure 122/76, pulse 80 |
| Ears, nose, mouth, and throat | Throat normal; no thrush; whispered voice heard at arm's length in both ears |
| Respiratory | Clear to auscultation bilaterally |
| Abdomen | Liver edge firm, 2 cm below the right costal margin, smaller than at diagnosis; no ascites; no tenderness |
| Skin | Port site clean; no jaundice or rash |
| Psychiatric | Composed, engaged, precise in his questions |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Right upper quadrant abdominal mass with weight loss: a dull ache under the right ribs and early fullness for about three months, 4 kg weight loss, and a firm, non-tender mass felt 4 cm below the right costal margin; no jaundice, fever, or itching. Ultrasound today: a 6.8 cm solid, heterogeneous mass in liver segments IV and V that cannot be separated from the gallbladder, which contains stones; the rest of the liver is smooth, with no ascites. Multiphase CT, tumor markers, hepatitis serology and medical oncology consultation arranged | resolved | confirmed | R19.01 | S — Synthetic presenting problem anchored to the documented right upper abdominal mass; superseded by the biopsy diagnosis. |
| Adenocarcinoma of the gallbladder invading the liver: core biopsy of the liver mass shows moderately differentiated adenocarcinoma (CK7 positive, CK20 and CDX2 negative), and multiphase CT and MRI show a 7.1 cm mass arising from the gallbladder fundus and invading liver segments IVb and V, with gallstones and two enlarged nodes in the hepatoduodenal ligament; no cirrhosis; alpha-fetoprotein normal, CA 19-9 raised. Clinical T3 N1 before staging laparoscopy (AJCC 8th edition). Synthetic modern episode linked to his documented final illness, described in life as liver cancer and at autopsy as gallbladder adenocarcinoma | active | confirmed | C23 | S — Synthetic modern diagnosis chosen to fit the documented findings: a mass involving the liver at operation and gallbladder adenocarcinoma at autopsy. |
| Resolved hepatitis B infection: hepatitis B surface antigen negative, total core antibody positive, surface antibody positive, HBV DNA undetectable; hepatitis C antibody negative. At risk of reactivation during chemotherapy and immunotherapy; monitored | active | confirmed | Z86.19 | S — Synthetic serology; not a claim that he had hepatitis B in his lifetime. No fetched source mentions hepatitis. |
| Peritoneal metastases from gallbladder adenocarcinoma: several 3 to 6 mm nodules on the parietal peritoneum and omentum at staging laparoscopy, biopsy positive for adenocarcinoma of the same type; stage IVB (M1), not resectable | active | confirmed | C78.6 | S — Synthetic finding anchored to the peritoneal metastases reported at autopsy. |
| Acute viral upper respiratory infection on day 10 of cycle 5 of chemoimmunotherapy: sore throat, runny nose and dry cough for three days, afebrile, with a neutrophil count of 1.6 x10^3/uL; rapid tests for SARS-CoV-2 and influenza negative; no sign of pneumonia or pneumonitis; resolved | resolved | confirmed | J06.9 | S — Synthetic acute illness; not a historical claim. |
Personalized prevention plan. A written copy was given to the patient. [S]
| Service | Status | Detail |
|---|---|---|
| Blood pressure screening | Completed today | 122/76 mmHg |
| Depression screening | Completed today | PHQ-2 score 1; PHQ-9 tracked at oncology visits |
| Unhealthy alcohol use screening | Completed today | Drinks rarely; none since treatment began |
| Tobacco use | Completed today | Never smoked |
| Colorectal cancer screening | Not indicated | Never screened; with metastatic gallbladder cancer the benefit of screening would not be realized, and he agreed not to pursue it now |
| Prostate cancer screening | Not indicated | Discussed; not offered while he has metastatic cancer |
| Lung cancer screening | Not indicated | Never smoked; he has CT scans of the chest every 2 to 3 months for his cancer |
| Diabetes screening | Not indicated | Not overweight; glucose 98 mg/dL at intake |
| HIV screening | Ordered | Never tested; once-in-a-lifetime test drawn today with his agreement |
| Hepatitis C screening | Up to date | Antibody negative at intake |
| Hepatitis B screening | Up to date | Resolved infection at intake; HBV DNA monitored during treatment; vaccination not needed |
| Influenza vaccine | Completed today | Inactivated vaccine given today |
| COVID-19 vaccine | Completed today | Given today; immunocompromised adults may need an additional dose, to be reviewed with the oncology team |
| Pneumococcal vaccine | Completed today | PCV20 given today because chemotherapy suppresses his immunity; no further pneumococcal dose needed |
| Zoster vaccine | Due | Recombinant zoster vaccine recommended for immunocompromised adults; first dose at the next visit, second one to two months later |
| Tetanus, diphtheria, and pertussis | Up to date | Tdap after a hand cut five years ago |
Immunizations given today: Influenza vaccine, 1924-1925 season (inactivated); COVID-19 vaccine, 1924-1925 formula; Pneumococcal conjugate vaccine (PCV20), for immunosuppression by chemotherapy [S]
Guideline basis: Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update (2017); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Colorectal Cancer: Screening (2021); Adult Immunization Schedule by Medical Condition and Other Indication (2026)
Follow-up: HIV result by phone. Cycle 7 as booked. Oncology visit before cycle 8 with restaging CT; first zoster vaccine dose then. Next preventive visit in one year. Next scheduled visit 1924-10-26: before cycle 8: restaging CT, toxicity review, low magnesium, and the plan for maintenance durvalumab. [S]
Voluntary advance care planning discussion of about 25 minutes, with his consent, building on his conversations with the palliative care team. He named a health care agent, recorded in the confidential part of the chart and not named here. He wants to be told everything plainly and to make his own decisions while he can. He wants treatment that lets him keep working and thinking clearly; if his illness reached the point where he could no longer communicate and there was no prospect of recovery, he would not want to be kept alive on machines and would want comfort care. He chose to wait before completing a portable medical order form and will revisit it with the palliative care team. To be revisited when treatment changes. [S]